JP2022542434A5 - - Google Patents
Info
- Publication number
- JP2022542434A5 JP2022542434A5 JP2022506384A JP2022506384A JP2022542434A5 JP 2022542434 A5 JP2022542434 A5 JP 2022542434A5 JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022542434 A5 JP2022542434 A5 JP 2022542434A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancers
- syndrome
- vitiligo
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881026P | 2019-07-31 | 2019-07-31 | |
| US62/881,026 | 2019-07-31 | ||
| PCT/US2020/044558 WO2021022186A1 (en) | 2019-07-31 | 2020-07-31 | Deuterated mk2 pathway inhibitors and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022542434A JP2022542434A (ja) | 2022-10-03 |
| JP2022542434A5 true JP2022542434A5 (OSRAM) | 2023-07-19 |
Family
ID=74228512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506384A Ceased JP2022542434A (ja) | 2019-07-31 | 2020-07-31 | 重水素化ｍｋ２経路阻害剤およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12403141B2 (OSRAM) |
| EP (1) | EP4003344A4 (OSRAM) |
| JP (1) | JP2022542434A (OSRAM) |
| KR (1) | KR20220041180A (OSRAM) |
| CN (1) | CN114206339A (OSRAM) |
| AU (1) | AU2020319879A1 (OSRAM) |
| BR (1) | BR112022001324A2 (OSRAM) |
| CA (1) | CA3149304A1 (OSRAM) |
| IL (1) | IL290045A (OSRAM) |
| MX (1) | MX2022001151A (OSRAM) |
| PH (1) | PH12022550029A1 (OSRAM) |
| WO (1) | WO2021022186A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022019349A2 (pt) * | 2020-03-27 | 2022-11-16 | Aclaris Therapeutics Inc | Forma cristalina, composição farmacêutica, comprimido e método para isolar um composto |
| IL307187A (en) | 2021-03-31 | 2023-11-01 | Xinthera Inc | MK2 inhibitors and their uses |
| KR20240035830A (ko) | 2021-07-09 | 2024-03-18 | 신테라, 인크. | 피리디논 mk2 저해제 및 이의 용도 |
| WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| TWI836822B (zh) * | 2021-12-29 | 2024-03-21 | 大陸商上海美悦生物科技發展有限公司 | p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| WO2023134764A1 (zh) | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物、其制备方法和应用 |
| US20230286950A1 (en) * | 2022-02-04 | 2023-09-14 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| WO2023165554A1 (zh) * | 2022-03-03 | 2023-09-07 | 深圳信立泰药业股份有限公司 | 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用 |
| WO2024149359A1 (zh) * | 2023-01-13 | 2024-07-18 | 上海美悦生物科技发展有限公司 | 苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途 |
| US20260115177A1 (en) * | 2023-01-13 | 2026-04-30 | Poolbeg Pharma (UK) Limited | Medicinal products and methods for the alleviation of cancer immunothera-py-associated cytokine release syndrome |
| WO2025093869A1 (en) * | 2023-11-01 | 2025-05-08 | Poolbeg Pharma (UK) Limited | P38 map kinase inhibitor for use in the treatment of inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080280886A1 (en) * | 2007-05-08 | 2008-11-13 | Auspex Pharmaceuticals, Inc. | Substituted ureas |
| SG176010A1 (en) * | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| US8575348B2 (en) * | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| CA2819889C (en) * | 2010-12-06 | 2020-12-15 | Confluence Life Sciences, Inc. | Substituted pyridinone-pyridinyl compounds |
| US9359300B2 (en) * | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| CA2917344C (en) * | 2013-06-07 | 2021-09-07 | Confluence Life Sciences, Inc. | Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| CZ2015601A3 (cs) * | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
| WO2017180589A1 (en) * | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
| WO2018229683A1 (en) * | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| CN111727042A (zh) * | 2017-12-06 | 2020-09-29 | 仁新医药私人有限公司 | 微管蛋白抑制剂 |
| EP4114411A4 (en) | 2020-03-02 | 2024-04-24 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
-
2020
- 2020-07-31 MX MX2022001151A patent/MX2022001151A/es unknown
- 2020-07-31 BR BR112022001324A patent/BR112022001324A2/pt not_active IP Right Cessation
- 2020-07-31 WO PCT/US2020/044558 patent/WO2021022186A1/en not_active Ceased
- 2020-07-31 CA CA3149304A patent/CA3149304A1/en active Pending
- 2020-07-31 JP JP2022506384A patent/JP2022542434A/ja not_active Ceased
- 2020-07-31 PH PH1/2022/550029A patent/PH12022550029A1/en unknown
- 2020-07-31 AU AU2020319879A patent/AU2020319879A1/en not_active Abandoned
- 2020-07-31 CN CN202080051376.9A patent/CN114206339A/zh active Pending
- 2020-07-31 EP EP20847487.4A patent/EP4003344A4/en active Pending
- 2020-07-31 KR KR1020227006713A patent/KR20220041180A/ko active Pending
- 2020-07-31 US US17/630,414 patent/US12403141B2/en active Active
-
2022
- 2022-01-23 IL IL290045A patent/IL290045A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531088A5 (OSRAM) | ||
| JP2021534244A5 (OSRAM) | ||
| ES2985542T3 (es) | Compuesto inhibidor de JAK y uso del mismo | |
| JP7580136B2 (ja) | Ｊａｋ阻害剤化合物及びその使用 | |
| JP2021502400A5 (OSRAM) | ||
| JP2020512315A5 (OSRAM) | ||
| JP2020511468A5 (OSRAM) | ||
| ES2277858T3 (es) | Heterociclos de nitrogeno biciclicos alquilamino sustituidos como inhibidores de proteina kinasa p38. | |
| DE60209381T2 (de) | N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase | |
| JP2022137194A (ja) | 神経刺激性ステロイド、組成物、およびその使用 | |
| JP2020128420A (ja) | Ｃｎｓ障害を処置するための組成物および方法 | |
| DE69920732T2 (de) | Bicyclische stickstoffheteroaryl verbindungen | |
| TWI842766B (zh) | 三環janus 激酶1 抑制劑及其組合物和方法 | |
| ES2430210T3 (es) | Derivados de 4-aminopirimidina como antagonistas del receptor de histamina H4 | |
| JP2017529367A5 (OSRAM) | ||
| EA027879B1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) | |
| CN111689959A (zh) | 作为fgfr4抑制剂的杂环化合物 | |
| CN113993585B (zh) | 双环jak抑制剂及其用途 | |
| CN113166193A (zh) | 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇 | |
| TW202227448A (zh) | 製備ｊａｋ抑制劑之方法及中間體 | |
| JP7164619B2 (ja) | 新規ブラジキニンｂ２受容体アンタゴニスト | |
| JP2022551316A5 (OSRAM) | ||
| CN120904157A (zh) | 杂芳基化合物及其制备方法和用途 | |
| AU2019206560B2 (en) | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators | |
| EP2516420B1 (en) | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |